Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NRL944
- Development stage
- Unknown
- Lead developer
- Norgine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NRL944 is a novel, soluble solid dispersion (SSD) formulation of the non-systemic antibiotic rifaximin, developed by Norgine. Standard rifaximin is characterized by very low aqueous solubility, which limits its efficacy in certain gastrointestinal environments. The SSD formulation is engineered to enhance the solubility and bioavailability of the drug within the gut lumen. Rifaximin exerts its therapeutic effect by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, thereby inhibiting bacterial RNA synthesis. In the context of hepatic encephalopathy, NRL944 targets ammonia-producing enteric bacteria, reducing the production and systemic absorption of ammonia and other gut-derived neurotoxins that contribute to cognitive impairment in patients with liver cirrhosis. NRL944 is primarily being investigated for the treatment and prevention of hepatic encephalopathy.
- Other names
- rifaximin soluble solid dispersion
Beyond the preview
Go deeper on NRL944.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NRL944.